Sign In

Allan Marchington

Managing Director, Head of Life Sciences at Intermediate Capital Group (ICG)

Allan Marchington is the Managing Director and Head of Life Sciences at Intermediate Capital Group (ICG), a position he has held since January 2021. In this role, he is responsible for overseeing the strategy and operations of ICG's Life Sciences Fund, which focuses on investments in the life sciences sector, including biotechnology and pharmaceuticals.13

Professional Background

Before joining ICG, Marchington was the Founder and Managing Partner of Bridge Valley Ventures, where he led investments in life sciences companies. He also co-founded Apposite Capital, further establishing his expertise in the field.15 His experience encompasses both investment and operational roles, emphasizing the importance of collaboration between management teams and investors to drive successful outcomes in drug development.1

Philosophy and Approach

Marchington advocates for a patient-centered investment philosophy, aiming to develop treatments that significantly impact patients' lives. His team at ICG combines extensive industry knowledge with a commitment to fostering long-term relationships with portfolio companies, ensuring they provide not just capital but also strategic support.13

Education and Skills

Allan Marchington's background is rooted in both science and business, allowing him to effectively navigate the complexities of life sciences investments. His approach involves rigorous due diligence and a focus on teams that have successfully brought drugs through clinical trials.14

For more insights into his professional journey, you can view his LinkedIn profile under the username allanmarchington.2

Highlights

Jul 15 · linkedin

Amolyt Pharma is a clinical stage biotechnology company. Its expert team delivers life-changing treatments to patients suffering from rare endocrine and related diseases. The former ICG Life Sciences team portfolio company has now joined AstraZeneca.

Capital at risk. Past performance is not a reliable indicator of future results.

#LifeSciences #PrivateMarkets #Alternatives #PrivateCapital

Mar 14 · linkedin

Today’s news of the definitive agreement for AstraZeneca to acquire Amolyt Pharma for up to $1.05bn, is a key moment highlighting the progress made by my team, ICG Life Sciences. 🔗 Press release: https://lnkd.in/eWP9M72Z

The transaction is expected to close in Q3 2024, subject to agreement conditions and regulatory approvals.

#LifeSciences #Biotechnology #RareDiseases #PrivateMarkets

Capital at risk. Past performance is not a reliable indicator of future results.

Related Questions

What are some of the key projects Allan Marchington has led at ICG?
How did Allan Marchington's experience at Bridge Valley Ventures prepare him for his role at ICG?
What makes Allan Marchington's approach to life sciences investment unique?
How does Allan Marchington's team at ICG collaborate with biotech companies?
What are the main challenges Allan Marchington faces in the life sciences sector?
Allan Marchington
Allan Marchington, photo 1
Allan Marchington, photo 2
Add to my network

Location

Greater London, England, United Kingdom